Dr. Spencer and Dr. Karl sit down with Dr. Sean Wharton, lead author on the OASIS-4 and ATTAIN-1 trials, to unpack the groundbreaking data behind the new oral GLP-1 medications. They discuss how oral semaglutide and orforglipron compare to injectables, what makes these molecules unique, and why 2026 could be the year obesity care changes forever.